Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome
Recruitment status was Not yet recruiting
Parathyroid hormone (PTH) gland calcium sensing receptor (CASR) regulates PTH secretion. CASR is also expressed in nephron thick ascending limb (TAL). Bartter syndrome (BS), a normotensive hypokalemic tubulopathy, may be due to mutations in different TAL channels, including the potassium channel ROMK. Mutations in CASR may also cause BS through its effects on ROMK function. However, it is unknown whether ROMK mutations exert any effects on CASR function and PTH physiology. Preliminary data from our center shows that PTH levels were specifically elevated in type II (where ROMK is mutated) and not in type IV (where another gene, Barttin is defective) BS, without a common explanation. We assume that the mutation in ROMK may cause a dysregulation of PTH secretion via possible interaction with CASR.
The purpose of this study is: to investigate the PT-gland function and regulation in BS.
Methods: Patients with BS type II and IV and normal controls will undergo a standard protocol of controlled ionic hypo- and hypercalcemia, during which PTH secretion, phosphate balance and calcium excretion will be followed. Calcium Vs PTH response curves will be generated and compared.
Expected impact and benefit: the results of this study will help understand the mechanisms of PTH regulation beyond CASR.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Case-control Study of the PTH Homeostasis in Adolescents and Young Adults With Bartter Syndrome|
Serum and urine will be later analyzed for FGF-23 and other key molecules in PTH homeostasis.
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Type II BS
Adolescents and young adults with type II Bartter syndrome
Type IV BS
Adolescents and adults with type IV Bartter syndrome
Age and sex- matched controls
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01021280
|Soroka University medical Center||Not yet recruiting|
|Beer Sheva, Israel, 84101|
|Contact: Daniel Landau, MD 972-8-6400546 firstname.lastname@example.org|
|Contact: Ruth Schreiber, MD 972-8-6400546 email@example.com|
|Principal Investigator: Daniel Landau, MD|
|Sub-Investigator: Ruth Schreiber, MD|